Ad
Wednesday, 28 September 2016
Actelion to investigate all-oral MS combination therapy
ZURICH (Reuters) - Swiss biotech group Actelion Ltd will investigate an all-oral combination therapy for patients with relapsing multiple sclerosis (RMS), it said, calling it the first study of this approach for treating the neurological disorder.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment